Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Capital Leases (2016)

Arrowhead Pharmaceuticals (ARWR) has disclosed Capital Leases for 6 consecutive years, with $378862.0 as the latest value for Q2 2016.

  • For the quarter ending Q2 2016, Capital Leases fell 36.38% year-over-year to $378862.0, compared with a TTM value of $378862.0 through Jun 2016, down 36.38%, and an annual FY2015 reading of $540792.0, down 28.69% over the prior year.
  • Capital Leases was $378862.0 for Q2 2016 at Arrowhead Pharmaceuticals, down from $430665.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $1.4 million in Q1 2012 and bottomed at $378862.0 in Q2 2016.
  • Average Capital Leases over 5 years is $878776.7, with a median of $838973.0 recorded in 2014.
  • The sharpest move saw Capital Leases decreased 15.0% in 2012, then tumbled 36.38% in 2016.
  • Year by year, Capital Leases stood at $1.2 million in 2012, then dropped by 18.03% to $1.0 million in 2013, then dropped by 29.93% to $705173.0 in 2014, then plummeted by 31.1% to $485842.0 in 2015, then fell by 22.02% to $378862.0 in 2016.
  • Business Quant data shows Capital Leases for ARWR at $378862.0 in Q2 2016, $430665.0 in Q1 2016, and $485842.0 in Q4 2015.